IRWD:NSD-Ironwood Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 10.98

Change

-0.05 (-0.45)%

Market Cap

USD 1.77B

Volume

1.54M

Average Target Price

USD 9.00 (-18.03%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the Canada and European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with GI diseases; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-19 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

+0.17 (+0.51%)

USD12.55B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
APHA Aphria Inc

+1.19 (+9.58%)

USD3.96B 41.54 454.68
CRON Cronos Group Inc

+0.16 (+1.46%)

USD3.93B 38.08 N/A
PCRX Pacira BioSciences, Inc

+0.17 (+0.23%)

USD3.20B 25.14 65.69
TLRY Tilray, Inc

+0.39 (+1.98%)

USD3.12B N/A N/A
ENDP Endo International plc

-0.06 (-0.84%)

USD1.64B N/A 9.98
SUPN Supernus Pharmaceuticals, Inc

+0.53 (+1.81%)

USD1.54B 12.12 7.71
ORGO Organogenesis Holdings Inc

-0.01 (-0.11%)

USD1.21B 456.50 77.95

ETFs Containing IRWD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.60% 11% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.60% 11% F 9% F
Trailing 12 Months  
Capital Gain -12.37% 51% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.37% 51% F 22% F
Trailing 5 Years  
Capital Gain 10.57% 70% C- 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.57% 70% C- 27% F
Average Annual (5 Year Horizon)  
Capital Gain 0.01% 61% D- 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.01% 61% D- 33% F
Risk Return Profile  
Volatility (Standard Deviation) 29.72% 77% C+ 49% F
Risk Adjusted Return 0.02% 61% D- 33% F
Market Capitalization 1.77B 91% A- 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 15.78 57% F 59% F
Price/Book Ratio 320.25 2% F 0% N/A
Price / Cash Flow Ratio 164.65 4% F 3% F
EV/EBITDA 14.06 62% D- 57% F
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 45.15% 98% A+ 97% A+
Return on Assets 21.68% 100% A+ 99% A+
Debt to Equity Ratio -437.52% 80% B- 98% A+
Technical Ratios  
Short Ratio 13.96 9% F 3% F
Short Percent 17.90% 23% F 11% F
Beta 1.41 45% F 36% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.